Skip to main content

Day: April 24, 2020

Micron Solutions Secures $1.2 Million SBA Loan under Paycheck Protection Program Provision of CARES Act

FITCHBURG, Mass., April 24, 2020 (GLOBE NEWSWIRE) — Micron Solutions, Inc. (OTCQB: MICR) (the “Company”), a diversified contract manufacturing organization, through its wholly-owned subsidiary, Micron Products, Inc., producing highly-engineered, innovative components requiring precision machining, injection molding and assembly services, announced today it received a $1.2 million loan (the “SBA Loan”) under the Paycheck Protection Program contained in the Coronavirus Aid, Relief and Economic Security Act (“CARES ACT”). The SBA Loan was obtained from Rockland Trust in Massachusetts.The SBA Loan has a two-year term with a fixed rate of one percent (1%) per annum and up to 100% of the SBA Loan may be forgiven based on the amount of funds used during the first eight week period following the loan origination date used towards payroll,...

Continue reading

Akerna Flash Report: 420 Cannabis Sales Create New Monday Record

DENVER, April 24, 2020 (GLOBE NEWSWIRE) — Business intelligence from Akerna (Nasdaq: KERN), a leading compliance technology provider and developer of the cannabis industry’s first seed-to-sale enterprise resource planning (ERP) software technology (MJ Platform®), shows sales on 420, a day of celebration for cannabis enthusiasts, made this years’ 420 the biggest Monday in 2020. Sales increased 111% over the previous Monday averages this year.“Overall, compared to last year’s daily percentage increase in sales, we’re slightly down this year. Considering the social nature of cannabis and current social distancing restrictions, it was still a strong sales day for the industry,” said Ryan Ballman, business intelligence engineer, Akerna. “Among the interesting things we noted in our business intelligence is a shift in what was purchased...

Continue reading

Draganfly Concludes COVID-19 Social Distancing Test with Westport Police Department

Los Angeles, CA, April 24, 2020 (GLOBE NEWSWIRE) — Draganfly Inc. (CSE: DFLY) (OTCQB: DFLYF) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer within the commercial Unmanned Aerial Vehicle (“UAV”), Remotely Piloted Aircraft Systems (“RPAS”), and unmanned vehicle sector, today announced that it has ended the development of a social distancing measurement test program with the Westport, CT Police Department.“While the development of the program is not moving forward in Westport, this was a valuable learning experience from which we are looking forward to evaluating the processes and lessons learned so the practice of social distancing has the right policies and procedures put in place to support this lifesaving technology,” said Cameron Chell, CEO Draganfly. “We look forward to working with...

Continue reading

BioSig to Host Conference Call on Recent Developments of Subsidiary ViralClear and its Broad-Spectrum Oral Anti-Viral Candidate Merimepodib for the Treatment of COVID-19

Westport, CT, April 24, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that it will be hosting an investor briefing to provide an update on the progress of its subsidiary ViralClear Pharmaceuticals, Inc, and recent developments of merimepodib (MMPD).The Company recently submitted an Investigational New Drug (IND) Application to the Food and Drug Administration (FDA) to commence a Phase II clinical trial with merimepodib as a treatment for COVID-19. The conference call is being held on Wednesday, April 29, 2020 at 11:00 AM ET.Kenneth L. Londoner, MBA, Chairman and CEO of BioSig Technologies, Inc. will be joined by Nick Spring, CEO of ViralClear Pharmaceuticals, Inc., Steven King, COO of ViralClear Pharmaceuticals, Inc., and Jerome Zeldis, M.D., Ph.D., Executive Chairman...

Continue reading

The Air France-KLM Group and Air France secure funding of €7 billion to help overcome the crisis and prepare for the future

Roissy, 24 April 2020The Air France-KLM Group and Air France secure funding of €7 billion to help overcome the crisis and prepare for the futureIn its communication of 9 April 2020, the Air France-KLM Group stated that, given the major impact of the Covid-19 crisis, which will weigh heavily on its EBITDA, and despite the significant measures taken to preserve its liquidity, it predicted that in the absence of additional funding, a liquidity injection would be necessary in the third quarter of 2020.The Air France-KLM Group, Air France and KLM therefore engaged in talks with the French and Dutch governments regarding the implementation of specific aid measures that would enable them to maintain their solvency.Following several weeks of discussions with the French state and banking institutions, the Air France-KLM Group and Air France were...

Continue reading

Le Groupe Air France-KLM et Air France bénéficient d’un financement à hauteur de 7 Mds€ pour traverser la crise et préparer l’avenir

Roissy, 24 avril 2020Le Groupe Air France-KLM et Air France bénéficient d’un financement à hauteur de 7 Mds€ pour traverser la crise et préparer l’avenirLe Groupe Air France-KLM a indiqué dans sa communication du 9 avril 2020 que compte tenu de l’impact majeur de la crise Covid-19, qui pèsera lourdement sur son EBITDA, et malgré les mesures importantes de préservation de trésorerie mises en place, ses prévisions mettaient en évidence qu’en l’absence de financement complémentaire un besoin de liquidités était attendu au troisième trimestre 2020.Le Groupe Air France-KLM, Air France et KLM ont dès lors engagé des discussions avec les Etats français et néerlandais sur la mise en œuvre de soutiens spécifiques qui leur permettraient de préserver leur solvabilité.Après plusieurs semaines de discussions, l’Etat français et des institutions bancaires,...

Continue reading

Tiziana Life Sciences Acquires a Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D for Treatment of Myelodysplastic syndrome and Acute Myeloid Leukemia

Nanoparticle Actinomycin formulation minimizes toxicity and enhances tolerability by slow release of drug to control Cmax in bloodThis announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.NEW YORK and LONDON, United Kingdom, April 24, 2020 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory, autoimmune and infectious diseases, announced today that it pursuant to an asset purchase agreement it has acquired all of the intellectual property relating to a nanoparticle-based formulation of Actinomycin D (Act D; a.k.a. Dactinomycin), from Rasna Therapeutics, Inc. (“Rasna”) to expand its pipeline for a consideration of an initial $120,000 upfront payment and milestone...

Continue reading

Standard & Poor’s downgrades Arion Bank’s long term credit rating to BBB but revised the outlook from negative to stable

Standard & Poor’s has downgraded Arion Bank’s long term credit rating from BBB+ to BBB but revised the outlook from negative to stable. Main comments from Standard & Poor’s:The global recession expected in 2020 due to COVID-19 will affect the open and concentrated Icelandic economy and its banks, despite a substantial government package to counteract the effects. It will also exacerbate some of the Icelandic banking industry´s weaknesses.The ‘BBB’ rating level and stable outlook factor in the solid market position of the bank in Iceland, which has a relatively advanced digitalized banking platform. In S&P’s view, the bank is well ahead of many other European banks in its preparation for technological disruption.The stable outlook indicates that S&P expects the bank to withstand the consequences of the looming...

Continue reading

Standard og Poor´s breytir lánshæfismati Arion banka, úr BBB+ í BBB en breytir horfum úr neikvæðum í stöðugar

Alþjóðlega lánshæfismatsfyrirtækið Standard & Poor’s hefur breytt lánshæfismati Arion banka til langs tíma, úr BBB+ í BBB og breytir horfum úr neikvæðum í stöðugar.Helstu athugasemdir frá Standard og Poor’s:Gert er ráð fyrir að áhrifa vænts alþjóðlegs efnahagssamdráttar á þessu ári sem er tilkominn vegna Covid 19 muni gæta í hinu opna íslenska hagkerfi og í bankakerfi landsins. Þetta er þrátt fyrir að stjórnvöld hafi ráðist í nokkuð umfangsmiklar mótvægisaðgerðir við samdrættinum. Efnahagssamdrátturinn nú mun draga fram veikleika sem til staðar eru í íslenska bankakerfinu að mati S&P.Lánshæfiseinkunin ‘BBB’ með stöðugum horfum endurspeglar trausta markaðsstöðu bankans á Íslandi. Bankinn er vel búinn að takast á við breytingar sem eru að verða í bankaþjónustu en hann býður uppá háþróaðar stafrænar bankalausnir og...

Continue reading

Islandsbanki hf.: S&P Global Ratings changes Íslandsbanki’s rating to BBB/A-2 rating with a stable outlook

Today, S&P Global Ratings (S&P) has lowered Íslandsbanki’s rating to BBB/A-2 from BBB+/A-2 and has changed the outlook to stable from negative.In its report, S&P expects Íslandsbanki to enter this crisis on a more solid foothold than the 2008 financial crisis. The ‘BBB’ rating level and stable outlook factor in the solid market position of the bank in Iceland, which has a relatively advanced digitalized banking platform. In S&P’s view, the bank is well ahead of many other European banks in its preparation for technological disruption. S&P also notes the Bank’s funding and liquidity metrics are adequate for the Bank’s risk profile, with comfortable liquidity ratios and liquid assets covering more than 3x the average short-term funding in 2019. Moreover, S&P states that the wholesale funding...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.